Abstract: The invention provides a human PRKG1 which is associated with cardiovascular diseases, respiratory diseases, dermatological diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, cancer, hemato-logical diseases, muscle-skeleton-diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, respiratory diseases, dermatological diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, cancer, hematological diseases, muscle-skeleton-diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PRKG1 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human GSK3B which is associated with cardiovascular diseases, cancer, metabolic diseases, hematological diseases, inflammation, respiratory diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, cancer, metabolic diseases, hematological diseases, inflammation, respiratory diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of GSK3B as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human GPR39 which is associated with the cardiovascular disorders, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR39 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human KLK3 which is associated with the endocrine system and hormone disorders, cardiovascular disorders, metabolic diseases, cancer disorders, neurological disorders, urological disorders and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of endocrine system and hormone disorders, cardiovascular disorders, metabolic diseases, cancer disorders, neurological disorders, urological disorders and reproduction disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK3 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human PPARD which is associated with the cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PPARD as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human AMDR which is associated with the cardiovascular diseases, infections, dermatological diseases, endocrinological diseases, metabolic diseases, gastroenterological diseases, cancer, inflammation, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, infections, dermatological diseases, endocrinological diseases, metabolic diseases, gastroenteroloigcal diseases, cancer, inflammation, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases, urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of AMDR as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human PRSC1 which is associated with the cardiovascular diseases, cancer, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, cancer, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PRSC1 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human PGCP which is associated with the cardiovascular diseases, endocrinological diseases, metabolic diseases, cancer, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, muscle-skeleton diseases, neurological diseases and urologial diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, endocrinological diseases, metabolic diseases, cancer, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, muscle-skeleton diseases, neurological diseases and urologial diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PGCP as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human NPEPPS which is associated with the cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, muscle-skeleton diseases, neurological diseases, respiratory diseases, inflammation and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, muscle-skeleton diseases, neurological diseases, respiratory diseases, inflammation and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of NPEPPS as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human TPP2 which is associated with the cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, gastroenterological diseases, cancer, inflammation, hematological diseases, respiratory diseases, muscle-skeleton diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, gastroenterological diseases, cancer, inflammation, hematological diseases, respiratory diseases, muscle-skeleton diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of TPP2 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human KLKB1 which is associated with the cardiovascular disorders, endocrine system and hormone disorders, metabolic diseases, gastrointestinal and liver diseases, inflammatory diseases, cancer disorders, muscle-skeleton disorders, neurological disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, endocrine system and hormone disorders, metabolic diseases, gastrointestinal and liver diseases, inflammatory diseases, cancer disorders, muscle-skeleton disorders, neurological disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of KLKB1 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human DPP10 which is associated with the cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases, urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of DPP10 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human RNPEP which is associated with the cardiovascular diseases, cancer, dermatological diseases, hematological diseases, neurological diseases, urological diseases, respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, cancer, dermatological diseases, hematological diseases, neurological diseases, urological diseases, respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of RNPEP as well as pharmaceutical compositions comprising such compounds.

Abstract: The present invention is directed to a polynucleotide and polypeptide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X2. The invention also provides the human MGAT-X2 associated with the cardiovascular diseases, metabolic diseases, muscle-skeleton disorders or dermatological diseases. The invention also provides assays for the identification of compounds useful for the modulation of cardiovascular diseases, dermatological diseases, metabolic diseases or muscle-skeleton disorders for treating of cardiovascular diseases, metabolic diseases, muscle-skeleton disorders or dermatological diseases associated with expression of the MGAT-X2. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X2 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human KLK8 which is associated with the cardiovascular diseases, dermatological diseases, neurological diseases, metabolic diseases, cancer disorders, urological diseases, gastroenterological diseases and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, neurological diseases, metabolic diseases, cancer disorders, urological diseases, gastroenterological diseases and reproduction disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK8 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human KLK13 which is associated with the hematological diseases, neurological diseases, metabolic diseases, endocrinological diseases, dermatological diseases, gastroenterological diseases, urological diseases, cancer disorders and inflammation. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, neurological diseases, metabolic diseases, endocrinological diseases, dermatological diseases, gastroenterological diseases, urological diseases, cancer disorders and inflammation. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK13 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human NPEPL1 which is associated with the cardiovascular diseases, cancer, dermatological diseases, gastroenterological diseases, metabolic diseases, inflammation, hematological diseases, respiratory diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, cancer, dermatological diseases, gastroenterological diseases, metabolic diseases, inflammation, hematological diseases, respiratory diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of NPEPL1 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human PDE1A which is associated with the cardiovascular disorders, endocrine system and hormone disorders, cancer disorders, gastrointestinal and liver diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, endocrine system and hormone disorders, cancer disorders, gastrointestinal and liver diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE1A as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human KLK12 which is associated with the gastrointestinal and liver diseases, cancer disorders, hematological diseases, inflammatory diseases, respiratory diseases, neurological disorders, cardiovascular disorders, reproduction disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of gastrointestinal and liver diseases, cancer disorders, hematological diseases, inflammatory diseases, respiratory diseases, neurological disorders, cardiovascular disorders, reproduction disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK12 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human EDG6 which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma. The invention also features compounds which bind to and/or activate or inhibit the activity of EDG6 as well as pharmaceutical compositions comprising such compounds.